[Visual field defect in a patient given sodium valporate then carbamazepine: possible effect of aminotransferase inhibition].
We report the case of a 25-years old woman with anti-epileptic drugs who presents a visual field defect similar to those described with vigabatrin even though she was successfully treated with valproic acid then carbamazepine without vigabatrin. The association with trichorrhexis nodosa, a hair disease sometimes associated with inherited perturbation of metabolism of urea cycle in which visual loss can occur, could suggest an aspecific inhibition of several aminotransferases which could explain different adverse effects of some anti-epileptic drugs (visual abnormalities, alopecia) perhaps in genetic predisposed patients.
Jung
Ph
P
Cabinet de Neurologie et d'Ophtalmologie, 30 ter Avenue de Brimont, 78400 Chatou.
Doussard-Lefaucheux
S
S
D000328:Adult; D000592:Amino Acid Metabolism, Inborn Errors / Q000201:enzymology / Q000235:genetics; D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use; D002220:Carbamazepine / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000188:drug therapy; D005074:Evoked Potentials, Visual / Q000502:physiology; D005260:Female; D006801:Humans; D000637:Transaminases / Q000378:metabolism*; D014508:Urea / Q000378:metabolism; D014635:Valproic Acid / Q000009:adverse effects* / Q000627:therapeutic use; D014786:Vision Disorders / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology*; D014794:Visual Fields / Q000187:drug effects*
D000927:Anticonvulsants; D002220:Carbamazepine; D014635:Valproic Acid; D014508:Urea; D000637:Transaminases